Online-Kurs

Minimally Invasive Options with Maximum Results in Treating Glaucoma

minimally invasive glaucoma surgery (MIGS)
online, USA
Veranstaltungsnummer: 33676
Zertifizierung: genehmigt
CME Max: 1
Kategorie:
Gebühren ab: gebührenfrei
verfügbare Plätze: unbegrenzt
Sprache: Deutsch

 Zum Kalender hinzufügen
  • Veranstalter
    Johns Hopkins School of Medicine
    Kurzbeschreibung
    This web-based symposium archive activity will provide ophthalmology clinicians with the knowledge and confidence to determine patient eligibility when considering the various MIGS devices available, determine which MIGS procedure or device is most appropriate for a particular patient, and manage the technical aspects of implementing MIGS. Information on potential role of impending drug delivery devices as they become available will also be discussed.
    Hinweis
    The Johns Hopkins School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Gebühren

    Fachärzte

    Teilnehmer max.
    unbegrenzt

    Gebühren ab
    kostenlos
    Hinweis
    This educational initiative is primarily intended for glaucoma specialists and comprehensive ophthalmologists. No prerequisites required.

    Ärzte/-innen in Weiterbildung

    Teilnehmer max.
    unbegrenzt

    Gebühren ab
    kostenlos
    Hinweis
    This educational initiative is primarily intended for glaucoma specialists and comprehensive ophthalmologists. No prerequisites required.
    Sponsoren
    Allergan Inc. (US)
  • Though eye drops for lowering intraocular pressure (IOP) are effective for treating glaucoma, patients are required to commit to lifelong treatment, which has proven difficult for many patients. Adherence and persistence rates to such medications are notoriously suboptimal. Invasive incisional surgery procedures, while very effective in reducing IOP, are associated with a number of complications. Minimally invasive glaucoma surgery (MIGS) has the potential to significantly improve the management of glaucoma for a variety of patients, including those with refractory disease, by reducing the need for IOP-lowering medications and delaying the need for more invasive procedures. MIGS fills an unmet treatment need between medical therapy and invasive surgery, though the exact place in treatment has yet to be defined. In addition, innovations in pharmacotherapy delivery devices, if approved, offer the potential to alter the paradigm for glaucoma patients who may not require surgical intervention. A number of implantable and external pharmacotherapy delivery devices are currently in development.

    The estimated time to complete this activity: 60 minutes.

     

    After attending this activity, the participant will demonstrate the ability to:

    • ASSESS recent clinical data regarding the efficacy and safety of various MIGS procedures.
    • UTILIZE relevant peer-reviewed data to identify appropriate candidates for MIGS.
    • INTEGRATE evolving clinical evidence into the selection of optimal, patient-specific MIGS procedures.
    • EVALUATE the clinical implications and potential treatment roles of current and emerging drug delivery devices for patients with glaucoma.
  • This event is virtual and takes 60 minutes.

    Johns Hopkins School of Medicine
    Turner Auditorium
    720 Rutland Ave
    US - MD 21287 Baltimore

  •  

    Please contact the organizer for further information.